The implications for future clinical trial design—if patient heterogeneity is ignored at baseline study selection, leading to potential confounds and misinterpretation of subsequent progression/complication rates—are highly significant.
← all excerpts
Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.
1
—
—